Subsequent to the phase I/II trial published by Gettinger and colleagues, a randomized phase II trial of brigatinib in crizotinib-refractory, ALK-positive NSCLC enrolled 112 subjects to receive brigatinib at 90 mg once daily (arm A) and 110 subjects to receive brigatinib at 180 mg daily with a 7-day lead-in at 90 mg daily (arm B; Kim et al., 2017). The gene discussed is ALK; the disease is non-small cell lung carcinoma.